A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept
NCT07075406
·
clinicaltrials.gov ↗
COMPLETED
Status
250
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndromes
Interventions
DRUG:
Luspatercept
Sponsor
Bristol-Myers Squibb